Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
mergers and acquisitions
Biotech
Sanofi mulling ‘moonshot’ M&A targets to survive Dupixent cliff
Sanofi is considering “moonshot” treatments among the acquisition targets to urgently replenish its pipeline, CFO François-Xavier Roger told Fierce.
James Waldron
Oct 30, 2026 3:27am
Biogen CEO ramps up strategy for early-stage R&D
Oct 28, 2026 11:00am
Why Corxel picked SPAC route to take obesity biotech public
Oct 27, 2026 6:00am
Novartis CEO keeps faith in Avidity despite $1.9B hit from fail
Oct 27, 2026 3:48am
EQT buys molecular diagnostics specialist Qiagen in a €10.8B deal
Oct 23, 2026 9:58am
Reverse mergers rebound to highest level since 2021: report
Oct 21, 2026 3:12am
